Cost-effectiveness Analysis of Long-effect versus Short-effect Granulocyte Stimulating Factor in the Prevention and Treatment of Bone Marrow Suppression Induced by Chemotherapy for Lung Malignancies
- VernacularTitle:长、短效粒细胞刺激因子预防和治疗肺部恶性肿瘤化疗所致骨髓抑制的成本-效果分析
- Author:
Yongna ZHANG
1
;
Baoxia HE
1
;
Zhenxin ZHANG
1
;
Jinhua CHEN
1
;
Wenzhou ZHANG
1
Author Information
1. Dept. of Pharmacy，the Affiliated Tumor Hospital of Zhengzhou University，Zhengzhou 450008，China
- Publication Type:Journal Article
- Keywords:
Recombinant human granulocyte stimulating factor injection;
Polyethylene glycol recombinant human granulocyte stimulating factor injection;
Lung malignancies;
Bone marrow suppression;
Cost-effectiveness analysis
- From:
China Pharmacy
2019;30(13):1826-1830
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： To compare the cost-effectiveness of long-effect and short-effect granulocyte stimulating factor in prevention and treatment of bone marrow suppression induced by chemotherapy for lung malignancies， and to provide reference for rational drug use in the clinic. METHODS： A retrospective analysis was conducted for 132 cases who used granulocyte stimulating factor to prevent and treat bone marrow suppression induced by chemotherapy for lung malignancies in the Affiliated Tumor Hospital of Zhengzhou University during Jan. 2017 to Jun. 2018. Among them， 60 cases were treated with Recombinant human granulocyte stimulating factor injection （short-effect， group A）， and 72 cases were treated with Polyethylene glycol recombinant human granulocyte stimulating factor injection （long-effect， group B）. Clinical efficacies， the occurrence of bone marrow suppression and ADR were compared between 2 groups. Cost was calculated， and cost-effectiveness analysis was conducted. Sensitivity analysis was conducted by down-regulating 20％ drug price. RESULTS： The total response rates of group A and B were 71.7％ and 75.0％， without statistical significance （P＞0.05）. There was no statistical significance in the incidence and duration of bone marrow suppression or the incidence of ADR （P＞0.05）. Average treatment costs of the two groups were （335.91±180.34） and （1 982.75±603.15） yuan； the cost of group A was significantly lower than that of group B （P＜0.05）. The cost-effectiveness ratio of them were 4.69 and 26.44， while group A as a reference， incremental cost-effectiveness ratio of group B was 494.55. The sensitivity analysis results were in agreement with the cost-effectiveness analysis. CONCLUSIONS： The effectiveness of Recombinant human granulocyte stimulating factor injection is similar to that of Polyethylene glycol recombinant human granulocyte stimulating factor injection for the prevention and treatment of bone marrow suppression induced by chemotherapy for lung malignancies. But the cost-effectiveness ratio of the former is lower than that of the latter.
